566th MEETING, CAMBRIDGE 219 expected. However, it was confirmed by measuring the accumulation of enzymically assayable ammonia. The very high K , for a-cyano-4-hydroxycinnamate measured under these conditions is also consistent with an acid matrix. The value of 6 p~ reported previously (Halestrap, 1975) was determined under conditions where the mitochondrial matrix was more alkaline than the medium. Addition of valinomycin to mitochondria metabolizing pyruvate caused the matrix to become alkaline, and pyruvate metabolism was increased considerably.
due to an increase in the intracellular concentration of cyclic AMP. Thus the ability of prostaglandins and hypothalamic extracts to stimulate growth-hormone release is enhanced in the presence of methylxanthine phosphodiesterase inhibitors, and the rise in cyclic AMP concentration apparently precedes the release of growth hormone (Steiner et al., 1970;  Schofield & McPherson, 1974) . Some additional evidence indicates that a redistribution of intracellular Caz+ mediates this increased growth-hormone release. Thus the increase in hormone release, but not cyclic AMP concentration, is inhibited by depletion of tissue Caz+, although verapamil (an inhibitor of Caz+ entry into cells) does not inhibit the hormone release @to et al., 1974) .
It has been suggested that somatostatin, a peptide isolated from sheep hypothalami and capable of inhibiting growth-hormone secretion, acts by modifying the cyclic nucleotide response in the pituitary. In support of this suggestion, it has been shown in rat pituitaries that somatostatin decreases the rise in cyclic AMP in the presence of prostaglandins and theophylline (Borgeat et al., 1974) , and that somatostatin increases the concentration of cyclic GMP (Kaneko et al., 1974) . We here report that somatostatin, VOl. 5 In (6) and (c) after 22min of perfusion, prostaglandin E2 (1 p~) and 1-methyl-3-isobutylxanthine ( 0 . 5 m~) were introduced in the absence (b) or presence (c) of somatostatin (1 pg/ml). Each point is the mean of three observations. at a concentration which blocks stimulation of growth-hormone release by prostaglandin and l-methyl-3-isobutylxanthine, does not modify the associated changes in ox pituitary cyclic AMP and cyclic G MP concentrations, 45Ca2+ efflux, or protein kinase activity.
Experimental
Bovine anterior-pituitary slices were prepared and incubated in Krebs-Ringer bicarbonate-buffered salt solution as previously described (Schofield & McPherson, 1974) . For determination of the effects of prostaglandins and somatostatin on growth-hormone release and 45Ca2+ efflux, slices were incubated for 4h in lml of incubationmedium containing 20pCi of 45Ca2+ (0.8mCi/mmol), and then perfused at 37°C in incubation medium containing 25 m~-C a C l~; 2min (4OOpl) fractions were collected. Growth hormone was measured by radioimniunoassay. For determination of cyclic AMP and cyclic GMP concentrations, tissue was frozen between aluminium blocks cooled in liquid N,, denatured at 100"C, homogenized and deproteinized in acid/ethanol as described by Albano et al. (1976) . Extracts were dried, the residues resuspended in Tris/HCI (SOm, pH7.4), and cyclic AMP was measured by a protein-binding assay (Brown et al., 1971) , and cyclic GMP by using rabbit antiserum raised to succinylated cyclic GMP conjugated to human serum albumin. For measurement of protein kinase activity, the tissue (70-100mg) was homogenized at 0°C in potassium phosphate ( 2 0 m~, pH6.5), containing EDTA (1 mM) and either sucrose ( 0 . 2 5~) or NaCl (O.~M), by using a Polytron homogenizer (~O S , position 3). The homogenate was centrifuged (Eppendorf 3200,2min), and protein kinase activity was measured in the supernatant with histone I1 AS (Sigma) as substrate and quenching the reaction as described by Wastila et al. (1971) .
Results and discussion
Addition of prostaglandin E, (1 p~) and I-methyl-3-isobutylxanthine ( 0 . 5 m~) to the perfusion medium caused a rapid increase in growth-hormone release (Fig. la) . At the Incubation conditions were: 0, control; 0 , somatostatin, 1 pg/ml; W, 1-methyl-3-isobutylxanthine, 0 . 5 m~; 0, l-methyl-3-isobutylxanthine, 0.5 m~, with somatostatin, 1 pg/ml. Each point is the mean of three observations. same time, a transient increase in the efflux of %az+ was observed (Fig. lb) . Since the external Caz+ concentration (2.5 m~) would be expected to be greater than the internal free Caz+ concentration, W a Z + efflux probably represents isotope exchange due possibly to changes in cell-membrane permeability or to redistribution of tissue Caz+. Somatostatin (1 pg/ml) completely blocked the release of growth hormone (Fig. la) , but did not modify the transient efflux of 45Caz+. This efflux therefore does not represent %aZ+ contained within growth-hormone secretory granules. Moreover, if efflux of %az+ and growth-hormone release are both consequences of an action of prostaglandin and isobutylmethylxanthine on CaZ+ translocation, the data suggest that somatostatin acts on secretion at a later stage. Addition of isobutylmethylxanthine to pituitary slices increased tissue cyclic GMP 8-fold over 30min (0.07-0.58pmol/mg wet weight) and increased cyclic AMP 14-fold (0.16-2.31 pmol/mg wet weight). Somatostatin (1 pg/ml) did not modify cyclic nucleotide concentrations in the presence or absence of isobutylmethylxanthine (Fig. 2) . The protein kinase activity ratio [for definition see Corbin et al. (1973) l was increased from 0.58f0.5 to 0.8850.06 (n = 7) after lOmin incubation in prostaglandin Ez (1 pg/ml) and isobutylmethylxanthine (0.5 mM); somatostatin (1 pg/ml) did not modify either the basal or the stimulated activity.
The inability of somatostatin to modify changes in CaZ+ distribution, cyclic nucleotide metabolism or protein kinase activity at a concentration which blocks the increase in growth-hormone release in response to prostaglandins and isobutylmethylxanthine strongly suggests that the peptide acts at a late stage in the secretory process. This work is supported by a grant from the Medical Research Council, and P. W. Y. holds a Medical Research Council Scholarship. We also thank Dr. R. Guillemin for the gift of synthetic linear somatostatin.
